NovoRapid flexpen 100 IU

NovoRapid flexpen 100 IU Insulin

 55.00 350.00

NovoRapid flexpen 100 IU Insulin has a faster reaction time and a shorter duration of action than soluble human insulin. In the case of subcutaneous injection into the abdominal wall, insulin begins to act within 10-20 minutes of injection

Special Discount! Click here to see more..


NovoRapid flexpen 100 IU Insulin is a fast acting insulin analogue.


The dosage of NovoRapid flexpen 100 IU Insulin depends on each individual and is determined according to the needs of the patient. Generally, NovoRapid is used in combination with prolonged or intermediate insulin administered at least once daily. Glycemic control and adjustment of insulin dosage are recommended to achieve optimal glycemic control.

Individual insulin requirements in adults and children are typically between 0.5 and 1.0 U / kg / day. When administered in a basal-bolus regimen, 50-70% of these needs can be covered by NovoRapid and the remainder by prolonged or intermediate insulin. A dose adjustment may also be required if the patient changes his physical activity, diet, or concomitant illness.

Special Population

As with all Insulin, it is necessary to intensify the glycemic control and adjust the dosage of insulin asparte individually in elderly patients and in patients with renal or hepatic disorders.

Use in children

No studies have been performed in children under 2 years of age. NovoRapid can only be used in these patients under close medical supervision.

In children, NovoRapid flexpen 100 IU Insulin may be preferred to soluble human insulin in cases where a rapid delay of action may be useful, for example, in planning meal injections (see section 5.1 Pharmacodynamic properties and Pharmacokinetic properties) .

In replacement of other insulins

NovoRapid flexpen 100 IU Insulin has a faster reaction time and a shorter duration of action than soluble human insulin. In the case of subcutaneous injection into the abdominal wall, insulin begins to act within 10-20 minutes of injection. Its maximum effect appears 1 to 3 hours after injection. Its duration of action is 3 to 5 hours.

Due to its faster action time, NovoRapid should generally be administered immediately before a meal. If necessary, NovoRapid can be injected shortly after a meal. Regardless of the site of injection, the delay of action remains faster than that of human insulin. Adjustment of NovoRapid dosage and basal insulin may be required when transferring other insulins.

Administration mode

Administration with FlexPen:

NovoRapid flexpen 100 IU Insulin is a pre-filled pen designed for use with NovoFine or NovoTwist needles.

FlexPen can be used to inject 1 to 60 units in 1 unit increments.

NovoRapid flexpen 100 IU Insulin is color-coded and accompanied by instructions that must be followed.

NovoRapid is administered subcutaneously by injection into the abdominal wall, thigh, upper arm, deltoid region or buttock region. Rotation of injection sites should always be carried out within the same area. As with all insulins, absorption is faster if the injection is done subcutaneously in the abdominal wall rather than at another injection site. The duration of action varies according to dose, injection site, blood flow, temperature and intensity of physical activity.

Continuous insulin subcutaneous perfusion (CSII):

NovoRapid may be administered by continuous subcutaneous insulin infusion (CSII) using an insulin infusion pump. CSII will be administered in the abdominal wall. The infusion points should be alternated.

When used in an insulin infusion pump, NovoRapid should never be mixed with any other insulin.

Patients treated with CSII will receive detailed instructions on the use of the pump and will use the tank and tubing suitable for the pump (see Special precautions for disposal and handling). The infusion equipment (tubing and cannula) must be replaced in accordance with the instructions given in the infusion kit infusion kit.

When NovoRapid is administered via CSII, the patient must have another source of insulin to use in the event of a pump failure.

Intravenous use:

If necessary, NovoRapid may also be administered by intravenous injection by health professionals.

Intravenous infusion systems containing NovoRapid 100 U / ml at insulin asparte concentrations ranging from 0.05 U / ml to 1.0 U / ml in 0.9% sodium chloride perfusion Of 5% or 10% glucose with 40 mmol / l of potassium chloride remain stable at room temperature for 24 hours in a polypropylene infusion bag.

Despite their stability over time, a certain amount of insulin will be adsorbed from the outset to the infusion bag. Blood sugar levels

Additional information


Novo Nordisk India Pvt Ltd


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.